Cargando…
PERK Pathway and Neurodegenerative Disease: To Inhibit or to Activate?
With the extension of life span in recent decades, there is an increasing burden of late-onset neurodegenerative diseases, for which effective treatments are lacking. Neurodegenerative diseases include the widespread Alzheimer’s disease (AD) and Parkinson’s disease (PD), the less frequent Huntington...
Autores principales: | Shacham, Talya, Patel, Chaitanya, Lederkremer, Gerardo Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996871/ https://www.ncbi.nlm.nih.gov/pubmed/33652720 http://dx.doi.org/10.3390/biom11030354 |
Ejemplares similares
-
Protein Misfolding and ER Stress in Huntington's Disease
por: Shacham, Talya, et al.
Publicado: (2019) -
A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models
por: Ganz, Javier, et al.
Publicado: (2020) -
The Role of PERK in Understanding Development of Neurodegenerative Diseases
por: Smedley, Garrett Dalton, et al.
Publicado: (2021) -
Oxidoreductases in Glycoprotein Glycosylation, Folding, and ERAD
por: Patel, Chaitanya, et al.
Publicado: (2020) -
PERK: a novel therapeutic target for neurodegenerative diseases?
por: Ma, Tao, et al.
Publicado: (2014)